Related Experiment Video

Updated: Dec 2, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.1K

[Potential therapeutic drugs for novel coronavirus pneumonia]

N F Nie1, Y He1

  • 1Department of Pulmonary and Critical Care Medicine, Daping Hospital, Army Medical University, Chongqing 400042, China.

Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases
|November 2, 2020
PubMed

Insights

Current COVID-19 treatments lack specific efficacy. This review examines existing drugs like lopinavir/ritonavir and novel therapies such as IL-6 monoclonal antibodies for treating coronavirus pneumonia.

Area of Science:

  • Virology
  • Infectious Diseases
  • Pharmacology

Background:

  • The COVID-19 pandemic remains a significant global health crisis.
  • No specific antiviral therapies are currently approved for treating COVID-19.
  • Existing treatments are repurposed drugs with varying efficacy and safety profiles requiring further validation.

Purpose of the Study:

  • To review current therapeutic strategies for COVID-19.
  • To highlight potential novel drug candidates for COVID-19 treatment.
  • To provide an overview of drugs under investigation for managing coronavirus pneumonia.

Main Methods:

  • Literature review of clinical trials and research on COVID-19 therapeutics.
  • Analysis of commonly used drugs in clinical practice for COVID-19.
  • Identification and discussion of emerging drug classes and therapies.

Main Results:

  • Several drugs, including lopinavir/ritonavir, chloroquine phosphate, and IFN-α, are used but require further clinical evaluation.
  • Emerging therapies like IL-6 monoclonal antibodies, tyrosine kinase inhibitors, and cell therapies show promise.
  • The efficacy and safety data for many COVID-19 treatments are still limited.

Conclusions:

  • There is an urgent need for effective and specific treatments for COVID-19.
  • Ongoing research into novel therapeutic agents is crucial for combating the pandemic.
  • Further clinical trials are essential to establish the definitive role of various drugs in COVID-19 management.

More Related Videos

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.7K
Assays for the Identification of Novel Antivirals against Bluetongue Virus12:02

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Published on: October 11, 2013

14.4K

Related Concept Videos

Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
867
Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
499
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
718
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
306
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
340
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
624